These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12903649)

  • 41. Cardiovascular risk reduction: the future of cholesterol lowering drugs.
    Bou Malham S; Goldberg AC
    Curr Opin Pharmacol; 2016 Apr; 27():62-9. PubMed ID: 26939026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CETP inhibitors to increase HDL cholesterol levels.
    Tall AR
    N Engl J Med; 2007 Mar; 356(13):1364-6. PubMed ID: 17387130
    [No Abstract]   [Full Text] [Related]  

  • 44. Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior.
    Simko V
    Bratisl Lek Listy; 2016; 117(11):625-627. PubMed ID: 28125886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular disease and dyslipidemia: beyond LDL.
    Pöss J; Custodis F; Werner C; Weingärtner O; Böhm M; Laufs U
    Curr Pharm Des; 2011; 17(9):861-70. PubMed ID: 21418031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
    Devendra GP; Whitney EJ; Krasuski RA
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):380-3. PubMed ID: 20693158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Statins, life style and treatment of hypercholesterolemia: the time is changing, criteria too].
    Pintó X
    Med Clin (Barc); 2006 Feb; 126(6):217-9. PubMed ID: 16510095
    [No Abstract]   [Full Text] [Related]  

  • 48. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The difficult road to cholesterol homeostasis].
    Joossens JV
    Verh K Acad Geneeskd Belg; 1984; 46(1):5-31. PubMed ID: 6331021
    [No Abstract]   [Full Text] [Related]  

  • 50. Where are we with probucol: a new life for an old drug?
    Yamashita S; Matsuzawa Y
    Atherosclerosis; 2009 Nov; 207(1):16-23. PubMed ID: 19457483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
    Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
    J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is C-reactive protein an additional, surrogate end-point for statin treatment?
    Kluft C
    Eur Heart J; 2002 May; 23(10):761-4. PubMed ID: 12009712
    [No Abstract]   [Full Text] [Related]  

  • 54. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
    Kural BV; Orem C; Uydu HA; Alver A; Orem A
    Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
    Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
    Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How should we define hypercholesterolemia?
    Tonkin AM
    Curr Atheroscler Rep; 2000 Jul; 2(4):273-4. PubMed ID: 11122753
    [No Abstract]   [Full Text] [Related]  

  • 58. New targets of high-density lipoprotein therapy.
    Nicholls SJ; Nissen SE
    Curr Opin Lipidol; 2007 Aug; 18(4):421-6. PubMed ID: 17620859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient information. How do I treat my high cholesterol?
    JAAPA; 2011 May; 24(5):64. PubMed ID: 21574537
    [No Abstract]   [Full Text] [Related]  

  • 60. Demystifying HDL Cholesterol-A "Human Knockout" to the Rescue?
    Khera AV; Ridker PM
    Clin Chem; 2017 Jan; 63(1):33-36. PubMed ID: 27881451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.